Palvella Therapeutics (PVLA) Interest Expenses (2014 - 2024)

Palvella Therapeutics (PVLA) reported Interest Expenses of $181000.0 for Q4 2024, down 17.73% quarter-over-quarter from $220000.0 in Q3 2024.

Palvella Therapeutics (PVLA) Interest Expenses (2014 - 2024) Analysis & Trends

Palvella Therapeutics (PVLA) has 3 years of Interest Expenses data on file, last reported at $181000.0 in Q4 2024.

Interest Expenses for Q4 2024 came in at $181000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $181000.0 (down 27.31% YoY), and the FY2024 annual result was $430000.0, changed N/A from the prior year.
Interest Expenses fell to $181000.0 in Q4 2024 per PVLA's latest filing, from $220000.0 in the prior quarter.
Over five years, Interest Expenses peaked at $220000.0 in Q3 2024 and troughed at $29000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int Expense (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-5.50 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-332,000.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	61,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-2,753.00
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-5.58 Mn
10	Palvella Therapeutics	1.49 Bn	1.23 Bn	-	-

Download Data